관리-도구

편집 파일: 1629477426.M752289P24325.server.saraya-global.com,S=12260,W=12451:2,

Envelope-to: roya.rouzbehani@saraya.world
Delivery-date: Sat, 21 Aug 2021 00:37:06 +0800
Content-Type: text/html; charset=utf-8
From: Office WulfHoeflich <office.wulfhoeflich@thefuturebridge.com>
To: roya.rouzbehani@saraya.world
Reply-To: office.wulfhoeflich@thefuturebridge.com
Subject: Unique Insights on Techno Commercial Trends for Disease Pattern &
 Therapeutics in Cardio Metabolic & Endocrine
Message-ID: <a0e4feb7-3d1a-83da-b76e-ec21ac2277b1@thefuturebridge.com>
Content-Transfer-Encoding: quoted-printable
MIME-Version: 1.0
Feedback-ID: MTEyMTc1OjIwMjEwODIwXzIyOg==:pepipostE
Date: Fri, 20 Aug 2021 22:07:01 +0530

Dear =
roya, My =
name is Wulf H=C3=B6flich and I head the Business Development for =
FutureBridge - a Research & Advisory firm providing techno-commercial =
insights across major industries for over two decades. We support =
the most Fortune 500 players like Roche, DSM, Reckitt =
Benckiser, STADA, Nestle, Clariant, 3M, BASF, etc. I am writing to you as we have a unique =
proposition for SARYRA on the Evolving =
Disease Pattern & Therapeutics in the area of Cardio Metabolic & =
Endocrine and we believe that reaching out to you would be most =
advisable given the ambit and responsibility of your profile. We are keen to introduce ourselves and =
share with you how companies are evaluating opportunities to identify and =
scientifically compare different biomarkers & targets, =
novel treatment modalities, and associated intellectual =
property. We shall also exhibit cases of evolving patient =
journey, impact of clinical guidelines on referral =
pathways, treatment algorithms, rising =
expectations of standard of care (SoC) across different =
lines of therapy and similar other cases. It will be interesting=
 for you to see how scientific intelligence program is being used by =
Innovation, R&D, Technology scouting, Strategy, M&A and Clinical =
development functions of leading Biopharma & Medtech companies to =
understand and act on complex therapeutic areas such Cardiovascular=
 & Metabolic Health and indications like Hypertension</str=
ong>, Diabetes (T1, T2 & Gestational), PAH, =
Hypercholosterolmia, Arrhythmias, Congenial heart disease=
, Cardiomyopathy, Rheumatic Heart Diseases, CAD, Thyroid, and more.=
 We would like to request thirty minutes of your time for=
 a digital meeting (30 minutes only) in the coming weeks to introduce to =
you our unique hyper intelligence and insights program on Animal Health & =
Therapeutics. Would any of the following slots work for you? If =
yes, please write back to me with your preference. If not, please suggest =
alternatives: <ul fr-original-style=3D"box-sizing: border-box;" =
style=3D"box-sizing: border-box; margin-top: 0px; margin-bottom: 9px;"><li =
fr-original-style=3D"box-sizing: border-box;" style=3D"box-sizing: =
border-box;">Tuesday, 31 August &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; =
&nbsp; &nbsp;09.00 to 09.30 CEST</li><li =
fr-original-style=3D"box-sizing: border-box;" style=3D"box-sizing: =
border-box;">Thursday, 02 September &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;07.00=
 to 07.30 CEST</li><li fr-original-style=3D"box-sizing: =
border-box;" style=3D"box-sizing: border-box;">Friday, 03 September &nbsp; &nbsp; &nbsp; &nbsp; =
&nbsp; &nbsp; &nbsp;09.00 to 09.30 CEST</li><li =
fr-original-style=3D"box-sizing: border-box;" style=3D"box-sizing: =
border-box;">Monday, 06 September &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; =
&nbsp;08.00 to 08.30 CEST</li><li fr-original-style=3D"box-si=
zing: border-box;" style=3D"box-sizing: border-box;">Tuesday, 07 September &nbsp; &nbsp; &nbsp; &nbsp; =
&nbsp; 07.00 to 07.30 CEST</li></ul>
 Best Regards, Wulf H=C3=B6flich SVP =E2=80=93 Business Development - =
Dipl.-Ing. (Univ.) Fut=
ureBridge UK</strong=
> 5, Chancery Lane, London EC4A 1BL United Kingdom T :+44 2034 787 710 <a href=3D"http://insider.futurebridge.=
com/r/2b572328187dd363f711d3f54?ct=3DYTo1OntzOjY6InNvdXJjZSI7YToyOntpOjA7cz=
oxNDoiY2FtcGFpZ24uZXZlbnQiO2k6MTtpOjUyOTA3O31zOjU6ImVtYWlsIjtpOjEwOTExO3M6N=
Doic3RhdCI7czoyMjoiNjExZmQwOGRhYTRmNjU2NjkzMjMyOSI7czo0OiJsZWFkIjtpOjExNTY0=
MDM2O3M6NzoiY2hhbm5lbCI7YToxOntzOjU6ImVtYWlsIjtpOjEwOTExO319&"></a> =
<a href=3D"http://insider.futurebridge.com/r/2b572328187dd363f711d3f54?=
ct=3DYTo1OntzOjY6InNvdXJjZSI7YToyOntpOjA7czoxNDoiY2FtcGFpZ24uZXZlbnQiO2k6MT=
tpOjUyOTA3O31zOjU6ImVtYWlsIjtpOjEwOTExO3M6NDoic3RhdCI7czoyMjoiNjExZmQwOGRhY=
TRmNjU2NjkzMjMyOSI7czo0OiJsZWFkIjtpOjExNTY0MDM2O3M6NzoiY2hhbm5lbCI7YToxOntz=
OjU6ImVtYWlsIjtpOjEwOTExO319&">www.futurebridge.com</a> 
<img src=3D"https://insider.futurebridge.com/media/images/fb_logo.jpg" =
/>
 
Please consider the =
environment before printing this email. 
FutureBridge=C2=AE is a registered =
trademark of Cheers Interactive (India) Private Limited. 
=E2=80=9CThis message is =
intended only for the person or entity to which it is addressed and =
contains confidential, proprietary and/or privileged information. If you =
have received this message in error, please notify the sender immediately =
and delete this message from your system. Reasonable precautions have been =
taken to ensure that this message is virus-free. However, Cheers =
Interactive (India) Private Limited does not accept any responsibility =
whatsoever for any loss or damage arising from the use of this message or =
any attachments herein=E2=80=9D.
 If you prefer not to receive any future =
email communication from FutureBridge for meeting request, please write to =
<a href=3D"mailto:meetings_unsubscribe@futurebridge.=
com">meetings_unsubscribe@futurebridge.com</a> to unsubscribe.=
<img height=3D"1" width=3D"1" src=3D"http://insider.=
futurebridge.com/email/611fd08daa4f6566932329.gif" alt=3D"" =
/>